News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics
UK-based antibody engineering experts Isogenica are proud to announce a new collaboration with the Frederick National Laboratory for Cancer Research in Maryland USA.
Wellmarker Bio and Isogenica today announced the signing of a Memorandum of Understanding (MoU). The MoU will serve as a foundation for increased cooperation between the two companies.
Isogenica-Phenotypeca collaboration spear-headed by SMART Grant award Isogenica are furthering their collaboration with Phenotypeca, whose platform will deploy yeast-display for multivalent...
Catch up on Isogenica’s latest activities.
As part of our KTP partnership between Aston University and Nottingham University, we’re developing and integrating an ML-assisted pipeline for faster discovery and optimisation of VHH antibodies for next-generation biotherapeutics.
Read how AstraZeneca researchers screened our highly diverse, fully synthetic VHH library for novel antibodies against phospholamban.
A collaboration with the University of Nottingham and Aston University Advances in computing and data science, such as machine learning (ML) and artificial intelligence (AI), are transforming all...
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
The advantages of VHH in Neurodegenerative Diseases.
Camelid heavy-chain only antibodies were discovered in the early 1990’s. Often referred to as VHH antibodies, they are a well characterized alternative to therapeutic IgG’s. Camelid heavy-chain only...
Isogenica are always looking to learn and connect at upcoming events and conferences.
Catch up with Isogenica’s news and activies through the latest Newsletters.
Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer cells. However, checkpoint inhibitor drugs don’t work for all patients, so the hunt is on for more targeted and personalised therapies that directly engage immune cells with cancer cells.
Introducing VHHantage™ allowing maximised diversity humanised VHH binders with significantly reduced liabilties, allowing the efficient discovery developable antibodies.
Isogenica have developed fully synthetic, in vitro plugandplay cassettebased approach to efficiently generate combinations of bi and trispecific VHH, exemplified in in vitro studies.